Nplex Biosciences operates in the biotechnology sector, specializing in the development of advanced proteomics solutions using nanotechnology. The company's core product, the nELISA, is a miniaturized and highly parallelized version of the classical sandwich ELISA immunoassay. This innovative platform allows for the scalable and cost-effective measurement of proteins, overcoming historical economic barriers associated with antibody-based proteomics. Nplex Biosciences primarily serves research teams in academic institutions, pharmaceutical companies, and biotech firms who require high-throughput protein profiling for their projects. The company generates revenue through the sale of its nELISA platform and associated consumables, as well as through service contracts for custom proteomics projects. By leveraging DNA nanotechnology, Nplex Biosciences has engineered a unique solution that deciphers the identity of proteins on micron-sized beads, enabling precise and efficient protein analysis. The market for Nplex Biosciences includes sectors focused on drug discovery, biomarker discovery, and personalized medicine. The business model is centered around providing a scalable and reliable proteomics platform that meets the high-throughput needs of its clients.

Keywords: nanotechnology, proteomics, nELISA, protein measurement, biotechnology, high-throughput, antibody-based, DNA nanotechnology, drug discovery, biomarker discovery.